Liquidia Corp.

Liquidia Corporation is a biopharmaceutical company focused on the development and commercialization of innovative therapies. Primarily engaged in the healthcare sector, Liquidia employs PRINT technology, a proprietary particle engineering platform that allows precise drug delivery by designing uniform particles in multiple sizes, shapes, and compositions. This technological advancement enables them to optimize therapeutic outcomes by improving the safety and efficacy profiles of pharmaceutical products. The company's efforts are directed towards inhalation therapies to treat rare and serious conditions, significantly impacting respiratory care as well as other medical fields. Based in Research Triangle Park, North Carolina, Liquidia plays a crucial role in advancing healthcare solutions by addressing unmet medical needs with its innovative approaches. Drawing significant attention within the pharmaceutical and life sciences industries, the company represents a critical part of the ecosystem dedicated to enhancing patient care through technology-driven drug design.